Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael G Dodds

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Clinical Pharmacology|November 19, 2016
Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)John P Gibbs, Sameer Doshi, Mita Kuchimanchi, et al.
The Journal of Prevention of Alzheimer'S Disease|June 1, 2025
Erratum to "INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(1): 100005.]Eric Siemers, Todd Feaster, Gopalan Sethuraman, et al.
The American Journal of Tropical Medicine and Hygiene|August 24, 2020
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19Craig R Rayner, Louis Dron, Jay J H Park, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's diseaseEric Siemers, Todd Feaster, Gopalan Sethuraman, et al.
Nature Communications|July 10, 2023
Author Correction: Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responsesFredrika Hellgren, Alberto Cagigi, Rodrigo Arcoverde Cerveira, et al.
Nature Communications|June 22, 2023
Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responsesFredrika Hellgren, Alberto Cagigi, Rodrigo Arcoverde Cerveira, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Clinical Pharmacology|November 19, 2016
Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)John P Gibbs, Sameer Doshi, Mita Kuchimanchi, et al.
The Journal of Prevention of Alzheimer'S Disease|June 1, 2025
Erratum to "INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(1): 100005.]Eric Siemers, Todd Feaster, Gopalan Sethuraman, et al.
The American Journal of Tropical Medicine and Hygiene|August 24, 2020
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19Craig R Rayner, Louis Dron, Jay J H Park, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's diseaseEric Siemers, Todd Feaster, Gopalan Sethuraman, et al.
Nature Communications|July 10, 2023
Author Correction: Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responsesFredrika Hellgren, Alberto Cagigi, Rodrigo Arcoverde Cerveira, et al.
Nature Communications|June 22, 2023
Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responsesFredrika Hellgren, Alberto Cagigi, Rodrigo Arcoverde Cerveira, et al.
Pageof 2